Using an Electrochemical Aptasensor to Early Detect Prostate Specific and Free Prostate Specific Antigens Released by Cancer Cells

2018 ◽  
Vol 30 (12) ◽  
pp. 2869-2877 ◽  
Author(s):  
João P. R. L. L. Parra ◽  
Bruno P. Crulhas ◽  
Caroline R. Basso ◽  
Flávia K. Delella ◽  
Gustavo R. Castro ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Electrochemical Aptasensor ◽  
Specific Antigens ◽  
Prostate Specific Antigens

414 VACCINATION WITH RAD5 CARRYING A FUSION CONSTRUCT OF PROSTATE-SPECIFIC ANTIGENS GENERATES EFFECTOR T CELLS

2011 ◽  
Vol 185 (4S) ◽  
Author(s):  
Felipe Rosso ◽  
Jeffrey Holzbeierlein ◽  
Peter Van Veldhuizen ◽  
Dev Karan
Keyword(s):  
T Cells ◽  
Effector T Cells ◽  
Fusion Construct ◽  
Specific Antigens ◽  
Prostate Specific Antigens

scholarly journals Oncolytic Virotherapy with Myxoma Virus

2020 ◽  
Vol 9 (1) ◽  
pp. 171 ◽  
Author(s):  
Masmudur M. Rahman ◽  
Grant McFadden
Keyword(s):  
Cancer Cells ◽  
Myxoma Virus ◽  
Oncolytic Viruses ◽  
Oncolytic Virotherapy ◽  
Host Immune System ◽  
Cancer Therapies ◽  
Cancer Models ◽  
Cancer Types ◽  
Specific Antigens ◽  
The Many

Oncolytic viruses are one of the most promising novel therapeutics for malignant cancers. They selectively infect and kill cancer cells while sparing the normal counterparts, expose cancer- specific antigens and activate the host immune system against both viral and tumor determinants. Oncolytic viruses can be used as monotherapy or combined with existing cancer therapies to become more potent. Among the many types of oncolytic viruses that have been developed thus far, members of poxviruses are the most promising candidates against diverse cancer types. This review summarizes recent advances that are made with oncolytic myxoma virus (MYXV), a member of the Leporipoxvirus genus. Unlike other oncolytic viruses, MYXV infects only rabbits in nature and causes no harm to humans or any other non-leporid animals. However, MYXV can selectively infect and kill cancer cells originating from human, mouse and other host species. This selective cancer tropism and safety profile have led to the testing of MYXV in various types of preclinical cancer models. The next stage will be successful GMP manufacturing and clinical trials that will bring MYXV from bench to bedside for the treatment of currently intractable malignancies.

scholarly journals A novel immobilization strategy for electrochemical detection of cancer biomarkers: DNA-directed immobilization of aptamer sensors for sensitive detection of prostate specific antigens

The Analyst ◽  
2015 ◽  
Vol 140 (8) ◽  
pp. 2628-2633 ◽  
Author(s):  
Zhugen Yang ◽  
Barbara Kasprzyk-Hordern ◽  
Sean Goggins ◽  
Christopher G. Frost ◽  
Pedro Estrela
Keyword(s):  
Electrochemical Detection ◽  
Cancer Biomarkers ◽  
Dna Aptamer ◽  
Sensitive Detection ◽  
Protein Biomarker ◽  
Specific Antigens ◽  
Prostate Specific Antigens

A novel immobilization strategy of DNA aptamer sensors for sensitive detection of a protein biomarker was developed based on DNA-directed immobilization.

scholarly journals Prospective investigation of change in the prostate-specific antigens after various urologic procedures

2015 ◽  
pp. 1213 ◽  
Author(s):  
Jong Park ◽  
Seung Chol Park ◽  
Yu Seob Shin ◽  
Li Tao Zhang ◽  
Dal Sik Kim ◽  
...  
Keyword(s):  
Specific Antigens ◽  
Prostate Specific Antigens ◽  
Prospective Investigation

scholarly journals Advances in biological treatment of melanoma

2018 ◽  
Vol 4 (2) ◽  
pp. 99
Author(s):  
Qazi Syed Irfanullah Shah ◽  
Xuefeng Wan ◽  
Akebaier Sulaiman ◽  
Paride Abliz ◽  
Yasir Ali Butt ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Metastatic Melanoma ◽  
Early Stage ◽  
Epigenetic Modification ◽  
Metastatic Cancer ◽  
Normal Growth ◽  
Oncogenic Mutations ◽  
Specific Antigens ◽  
Living Organisms ◽  
Murine Sarcoma

Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Metastatic disease have a grave prognosis in comparison to early stage metastatic cancer where surgical treatment can benefit the patients thus traditional chemotherapy regimens have been found to offer relatively little survival benefit. Treatment of advanced or metastatic melanoma includes involvement of biological modalities such as immunotherapeutic approaches, targeted therapies and epigenetic modification therapies. The goal of immunotherapy for cancer is to provide an effective anticancer immune response. These biological therapies restore or increase the activities of specific immune-system components and counteract immunosuppressive signals produced by cancer cells. Monoclonal antibodies, are laboratory-produced antibodies that bind to specific antigens expressed by cells, such as a protein that is present on the surface of cancer cells but is absent from normal cells. They interfere with the action of proteins that are necessary for tumor growth. When bound to bevacizumab, VEGF cannot interact with its cellular receptor, preventing the signaling that leads to the growth of new blood vessels. MAb’s that bind to cell surface growth factor receptors prevent the targeted receptors from sending their normal growth-promoting signals. The targeted therapeutic agents modulate specific pro-oncogenic mutations such as v-Raf murine sarcoma viral oncogene homolog B (BRAF), MEK inhibitors and CDK4/CDK6, PTEN and GNAQ/GNA11 genes. This review summarizes the biological agents and newer modalities of treatments, and their recent advancements and contributions in the treatment of patients with metastatic melanoma.

scholarly journals Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Maryam Hosseindokht ◽  
Hamid Bakherad ◽  
Hamed Zare
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Cancer Cells ◽  
Target Therapy ◽  
Main Body ◽  
Prostate Cancer Cells ◽  
New Horizons ◽  
Large Size ◽  
Cancer Antigens ◽  
Specific Antigens

Abstract Background Prostate cancer is one of the most common cancers in men and its incidence has increased dramatically in the last decade. This increase in the detection of this type of cancer is based more on the detection of PSA or PSMA antigens as the most important specific antigens of this cancer, and this early detection has greatly helped in the more optimal treatment of patients. Main body Many methods have been proposed by researchers for early detection of prostate cancer, but most of the methods used today to detect this type of cancer have been using classical antibodies. Although classical antibodies are able to detect tumor cell markers, but instability, large size, costly and laborious production, and random immobility characteristics, causes many problems. Nanobodies or VHHs, which are derived from camel heavy chain antibodies, have special advantages and have eliminated the disadvantages of classical antibodies which makes them attractive to use in biosensors and cancer diagnostic kits. The research that has been done so far shows that the introduced nanobodies are created for the purpose of targeting, detecting and sensing prostate cancer cells with two main purposes. The first is the efficient identification of prostate cancer and the second is the elimination of cancer cells. Conclusion Research shows the use of specific nanobodies against prostate cancer antigens in the design of biosensors and target therapy will be very interesting. In this review article, these nanobodies are introduced and categorized based on their performance.

Sign in / Sign up

Export Citation Format

Share Document